Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMBITIOUS
2010-018559-84Phase 2Completed
- Sponsor
- Technical University of Munich
- Start
- May 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of omalizumab in atopic dermatitis (AD), sponsored by Technical University of Munich. Primary endpoint: Primary objectives. Started May 2010; status: completed.
02
Drugs
omalizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2010-018559-84.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018559-84.